Study Details
A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause
Clinicaltrials.gov ID
Astellas Study ID
2693-CL-0307
EudraCT ID
N/A
Condition
Hot Flashes
Phase
Phase 3
Age
40 years - 65 years
Sex
Female
Product
fezolinetant
Type
Interventional
Trial Dates
Jul 2020 - Jun 2022
Masking
None (Open Label)
Enrollment number
150
A Single-Arm Phase 3 Clinical Study to Investigate the Long-Term Safety of Fezolinetant in Women in China Suffering from Vasomotor Symptoms (Hot Flashes) Associated with Menopause
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site CN86020
Kunming, China
Site CN86012
Hangzhou, China
Site CN86004
Shenzhen, China
Site CN86024
Fuzhou, China
Site CN86015
Beijing, China
Site CN86032
Chengdu, China
Site CN86025
Wuhan, China
Site CN86042
Guangzhou, China
Site CN86022
Guangzhou, China
Site CN86005
Hunan, China
Site CN86009
Shanghai, China
Site CN86011
Shanxi, China
Site CN86014
Jiangsu, China
Site CN86007
Nanjing, China
Site CN86002
Beijing, China
Site CN86037
Liuzhou, China
Site CN86030
Tianjin, China
Site CN86001
Guangzhou, China
Site CN86006
Nanjing, China
Site CN86026
Suzhou, China
Site CN86018
Nanning, China
Site CN86036
Tianjin, China
Site CN86008
Hangzhou, China
Site CN86010
Jinlin, China
Site CN86029
Beijing, China
Site CN86019
Guangzhou, China
Site CN86028
Shijiazhuang, China
Site CN86027
Lanzhou, China
Site CN86039
Jiangsu, China
Site CN86034
Ningxia Hui Nationality Autonomous Region, China
Site CN86013
Guangxi, China
Site CN86038
Taiyuan, China
Site CN86040
Guangzhou, China
Site CN86023
Guizhou, China